On May 10, 36 Kr, a well-known Chinese venture capital platform, released the 2023 "36 Under 36" list of entrepreneurs and investors, which has garnered extensive trust and attention within the venture capital community.
The "36 Under 36" event has been held for seven years, selecting young talents under the age of 36 and aiming to identify potential great entrepreneurs at an early stage. The entrepreneurs on the list primarily come from high technology fields such as smart hardware, new energy, industrial upgrading, and healthcare, and are regarded as future key figures in China's business world. Dr. Yugang Guo's inclusion in the list signifies the recognition of his leadership, as well as Leman Biotech's R&D progress and industry influence by the esteemed panel.
Dr. Yugang Guo completed his undergraduate and PhD degrees at the University of Science and Technology of China and served as a Scientific collaborator at the Swiss Federal Institute of Technology Lausanne (EPFL) from 2017 to 2022. Upon returning to China in February 2022, Dr. Yugang Guo embarked on establishing Leman Biotech, swiftly assembling a high-quality and efficient team of 16 members within a year, with 70% of the top-level R&D staff boasting rich industrialization experience from renowned domestic and international universities. Under his guidance, the company has been honored with over ten national, provincial, municipal, or industry accolades, while several R&D pipelines progress smoothly. Notably, the metabolism-enhanced CAR-T cell therapy has advanced to the IIT clinical research stage. Furthermore, Dr. Yugang Guo has been selected as a national high-level overseas young talent and bestowed with the title of Shenzhen U30 Outstanding Young Science and Technology Entrepreneur by the China Association for Science and Technology.
